7.49
price up icon0.40%   0.03
after-market 시간 외 거래: 7.49
loading
전일 마감가:
$7.46
열려 있는:
$7.19
하루 거래량:
942.25K
Relative Volume:
1.30
시가총액:
$574.53M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-2.3703
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
-23.18%
1개월 성능:
-34.93%
6개월 성능:
-33.89%
1년 성능:
+1.77%
1일 변동 폭
Value
$6.8507
$7.78
1주일 범위
Value
$6.8507
$9.68
52주 변동 폭
Value
$4.92
$17.00

레플리뮨 Stock (REPL) Company Profile

Name
명칭
Replimune Group Inc
Name
전화
(781) 222-9600
Name
주소
500 UNICORN PARK, WOBURN, MA
Name
직원
0
Name
트위터
@Replimune
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
REPL's Discussions on Twitter

REPL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
REPL
Replimune Group Inc
7.49 574.53M 0 -209.96M -176.27M -3.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

레플리뮨 Stock (REPL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-08-28 개시 ROTH MKM Buy
2023-04-17 재개 Piper Sandler Overweight
2021-11-19 개시 Piper Sandler Overweight
2021-10-15 재개 BTIG Research Buy
2020-11-17 개시 BTIG Research Buy
2020-11-02 개시 Jefferies Buy
2020-10-15 업그레이드 H.C. Wainwright Neutral → Buy
2020-07-01 다운그레이드 H.C. Wainwright Buy → Neutral
2020-05-05 개시 Barclays Overweight
2019-09-04 개시 ROTH Capital Buy
2019-07-23 개시 Chardan Capital Markets Buy
2019-07-12 업그레이드 JP Morgan Neutral → Overweight
2019-07-08 개시 H.C. Wainwright Buy
2019-04-25 개시 Wedbush Outperform
2019-01-23 다운그레이드 JP Morgan Overweight → Neutral
2018-08-14 개시 JP Morgan Overweight
2018-08-14 개시 Leerink Partners Outperform
모두보기

레플리뮨 주식(REPL)의 최신 뉴스

pulisher
Apr 03, 2025

Teacher Retirement System of Texas Takes $189,000 Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

Replimune Group (NASDAQ:REPL) Trading Down 7.6%What's Next? - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy - The Manila Times

Apr 01, 2025
pulisher
Mar 30, 2025

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Swiss National Bank - Defense World

Mar 30, 2025
pulisher
Mar 25, 2025

Charles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 25, 2025
pulisher
Mar 22, 2025

Victory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Bank of New York Mellon Corp Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Holdings Cut by AlphaQuest LLC - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Average Price Target from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 17, 2025

Arizona State Retirement System Invests $156,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 17, 2025
pulisher
Mar 12, 2025

Financial Metrics Check: Replimune Group Inc (REPL)’s Ratios for Trailing Twelve Months - The Dwinnex

Mar 12, 2025
pulisher
Mar 07, 2025

Replimune Group Appoints New Director, Grants Stock Options By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Replimune Group Appoints New Director, Grants Stock Options - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Replimune Group Appoints Michael Goller To Board, Increases Board Size To Ten -March 07, 2025 at 05:04 pm EST - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -March 07, 2025 at 04:11 pm EST - Marketscreener.com

Mar 07, 2025
pulisher
Mar 06, 2025

Rhumbline Advisers Grows Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs - Bain Capital

Mar 06, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Mar 05, 2025
pulisher
Mar 01, 2025

JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World

Mar 01, 2025
pulisher
Feb 24, 2025

Replimune Group (NASDAQ:REPL) Stock Price Up 6.1%What's Next? - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Brokerages - Defense World

Feb 23, 2025
pulisher
Feb 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update - MarketBeat

Feb 20, 2025
pulisher
Feb 18, 2025

Replimune's SWOT analysis: oncolytic immunotherapy stock poised for FDA approval - Investing.com

Feb 18, 2025
pulisher
Feb 17, 2025

Possible Bearish Signals With Replimune Group Insiders Disposing Stock - Simply Wall St

Feb 17, 2025
pulisher
Feb 17, 2025

Leerink Partnrs Predicts Weaker Earnings for Replimune Group - Defense World

Feb 17, 2025
pulisher
Feb 17, 2025

FY2025 EPS Estimates for Replimune Group Lowered by Wedbush - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Replimune Group (NASDAQ:REPL) Announces Quarterly Earnings Results - MarketBeat

Feb 17, 2025
pulisher
Feb 16, 2025

HC Wainwright Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock - MarketBeat

Feb 16, 2025
pulisher
Feb 14, 2025

Replimune stock target raised to $22 at H.C. Wainwright - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Replimune stock target raised to $22 at H.C. Wainwright By Investing.com - Investing.com Australia

Feb 13, 2025
pulisher
Feb 12, 2025

Replimune: A Misunderstood Contender In Oncolytics (NASDAQ:REPL) - Seeking Alpha

Feb 12, 2025
pulisher
Feb 12, 2025

Wedbush Raises Replimune Group's Price Target to $19 From $16, Keeps Outperform Rating - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Group Inc. (REPL) reports earnings - Quartz

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Group, Inc. SEC 10-Q Report - TradingView

Feb 12, 2025
pulisher
Feb 12, 2025

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

FDA Fast-Tracks Replimune's Melanoma Treatment as Cash Reserves Hit $536M in Q3 Report - StockTitan

Feb 12, 2025
pulisher
Feb 10, 2025

Top Wealth Group Holding Ltd (TWG)’s financial ratios: A comprehensive overview - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Metric Analysis: Nvni Group Ltd (NVNI)’s Key Ratios in the Limelight - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Feb 10, 2025

레플리뮨 (REPL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
자본화:     |  볼륨(24시간):